Royalty Pharma earnings were $1.1B for the trailing 12 months ending Mar 31, 2025, with 38% growth year over year. The latest RPRX earnings report on Mar 31, 2025 announced Q1 2025 earnings of $238.3M, up 14.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RPRX reported annual earnings of $859.0M, with -24.3% growth. The next RPRX earnings date is Aug 6, 2025.
RPRX past earnings growth
How has RPRX's earnings growth performed historically?
On RPRX's earnings call on Invalid Date, Royalty Pharma (NASDAQ: RPRX) reported Q1 2025 earnings per share (EPS) of $0.55, up 5,400% year over year. Total RPRX earnings for the quarter were $238.35 million. In the same quarter last year, Royalty Pharma's earnings per share (EPS) was $0.01.
The next RPRX earnings date is Invalid Date. Add RPRX to your watchlist to be reminded of Royalty Pharma's next earnings date.
Is Royalty Pharma profitable or losing money?
As of the last Royalty Pharma earnings report, Royalty Pharma is currently profitable. Royalty Pharma's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $1.09 billion, a 36.76% increase year over year.
What was RPRX's earnings growth in the past year?
As of Royalty Pharma's earnings date in Invalid Date, Royalty Pharma's earnings has grown 37.99% year over year. This is 27.03 percentage points higher than the US Biotechnology industry earnings growth rate of 10.96%. RPRX earnings in the past year totalled $1.09 billion.
What are Royalty Pharma's earnings expectations?
The current EPS estimate for Royalty Pharma's earnings report in Invalid Date is $1.04.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.